Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " BID" to " twice per day") |
|||
Line 45: | Line 45: | ||
*[[Aspirin]] 100 mg PO once per day | *[[Aspirin]] 100 mg PO once per day | ||
**[[:Category:Low_molecular_weight_heparins|LMWH]] in "intolerant" patients | **[[:Category:Low_molecular_weight_heparins|LMWH]] in "intolerant" patients | ||
− | *[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO | + | *[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO twice per day two days per week |
'''Monthly cycles, continued until progression or excess toxicity''' | '''Monthly cycles, continued until progression or excess toxicity''' |
Revision as of 21:32, 24 January 2019
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Section editor | |
---|---|
Andrew J. Cowan, MD Seattle, WA |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
RD
back to top |
RD: Revlimid (Lenalidomide) & Dexamethasone
Regimen
Study | Evidence |
---|---|
Nozza et al. 2017 | Phase II, <20 pts |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per week
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
Monthly cycles, continued until progression or excess toxicity
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed